Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Selexipag

FDA-approved product (tablet, oral), marketed as Selexipag, Uptravi.

Registered studies
41
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Selexipag
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Idiopathic and/or familial pulmonary arterial hypertension
  • Idiopathic pulmonary arterial hypertension
  • Pulmonary arterial hypertension
  • Pulmonary hypertension
  • Recurrent thrombophlebitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
Prostacyclin Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

41registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Selexipag in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Selexipag with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag

    NCT04567602 · start 2020-10-06

    Registered record
    Registry ID
    NCT04567602
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    PAH medication
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-10-06
    Completion
    2024-03-05
    Enrolment
    372

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionPAH medication
    PhaseNot recorded
    Registry statusCompleted

  • Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension

    NCT04309838 · start 2020-03

    Registered record
    Registry ID
    NCT04309838
    Conditions
    Pulmonary Arterial Hypertension; PAH
    Interventions
    Treprostinil via implanted pump
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-03
    Completion
    2021-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension; PAH
    InterventionTreprostinil via implanted pump
    PhaseNot recorded
    Registry statusUnknown

  • A Study of Selexipag in Healthy Male Participant

    NCT04266756 · start 2020-01-23

    Registered record
    Registry ID
    NCT04266756
    Conditions
    Healthy
    Interventions
    Selexipag matrix tablet; Selexipag encapsulated pellets; Selexipag Immediate-release (IR) tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-23
    Completion
    2020-08-14
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSelexipag matrix tablet; Selexipag encapsulated pellets; Selexipag Immediate-release (IR) tablet
    PhasePhase 1
    Registry statusCompleted

  • A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

    NCT04175600 · start 2020-01-16

    Registered record
    Registry ID
    NCT04175600
    Conditions
    Hypertension, Pulmonary
    Interventions
    Selexipag; Placebo; Standard of Care (SOC): Endothelin receptor antagonist; SOC: Phosphodiesterase type 5 (PDE-5) inhibitor; SOC: Soluble guanylate cyclase stimulator
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-01-16
    Completion
    2027-10-01
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionSelexipag; Placebo; Standard of Care (SOC): Endothelin receptor antagonist; SOC: Phosphodiesterase type 5 (PDE-5) inhibitor +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

    NCT03689244 · start 2019-01-23

    Registered record
    Registry ID
    NCT03689244
    Conditions
    Chronic Thromboembolic Pulmonary Hypertension
    Interventions
    Selexipag; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2019-01-23
    Completion
    2022-06-07
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Thromboembolic Pulmonary Hypertension
    InterventionSelexipag; Placebo
    PhasePhase 3
    Registry statusTerminated

  • A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

    NCT03492177 · start 2018-07-23

    Registered record
    Registry ID
    NCT03492177
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    selexipag (Uptravi)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-07-23
    Completion
    2026-12-31
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    Interventionselexipag (Uptravi)
    PhasePhase 2
    Registry statusActive not recruiting

  • A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects

    NCT03496506 · start 2018-03-05

    Registered record
    Registry ID
    NCT03496506
    Conditions
    Healthy Subjects
    Interventions
    Selexipag; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-03-05
    Completion
    2018-05-18
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionSelexipag; Clopidogrel
    PhasePhase 1
    Registry statusCompleted

  • Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

    NCT03187678 · start 2017-12-04

    Registered record
    Registry ID
    NCT03187678
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    i.v. selexipag; oral selexipag (Uptravi)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-04
    Completion
    2018-05-29
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    Interventioni.v. selexipag; oral selexipag (Uptravi)
    PhasePhase 3
    Registry statusCompleted

  • Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

    NCT03078907 · start 2017-11-08

    Registered record
    Registry ID
    NCT03078907
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Selexipag; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-11-08
    Completion
    2020-02-10
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionSelexipag; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

    NCT03016468 · start 2017-05

    Registered record
    Registry ID
    NCT03016468
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Parenteral Remodulin (treprostinil) injection; Oral Treprostinil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2017-05
    Completion
    2018-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionParenteral Remodulin (treprostinil) injection; Oral Treprostinil
    PhasePhase 2
    Registry statusWithdrawn

  • A Registry for Patients Taking Uptravi

    NCT03278002 · start 2016-11-01

    Registered record
    Registry ID
    NCT03278002
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-11-01
    Completion
    2021-09-21
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects

    NCT02791815 · start 2016-07

    Registered record
    Registry ID
    NCT02791815
    Conditions
    Healthy Subjects
    Interventions
    Midazolam; Selexipag
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-07
    Completion
    2016-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionMidazolam; Selexipag
    PhasePhase 1
    Registry statusCompleted

  • Comparison of Two Dose Strengths of Selexipag in Healthy Adults

    NCT02745860 · start 2016-06

    Registered record
    Registry ID
    NCT02745860
    Conditions
    Healthy Subjects
    Interventions
    Selexipag (adult formulation); Selexipag (pediatric formulation)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06
    Completion
    2016-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionSelexipag (adult formulation); Selexipag (pediatric formulation)
    PhasePhase 1
    Registry statusCompleted

  • A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects

    NCT02770222 · start 2016-06

    Registered record
    Registry ID
    NCT02770222
    Conditions
    Healthy Subjects
    Interventions
    Selexipag; Gemfibrozil; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06
    Completion
    2016-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionSelexipag; Gemfibrozil; Rifampicin
    PhasePhase 1
    Registry statusCompleted

  • The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

    NCT02558231 · start 2016-05-01

    Registered record
    Registry ID
    NCT02558231
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Macitentan; Tadalafil; Selexipag
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-05-01
    Completion
    2020-04-20
    Enrolment
    247

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionMacitentan; Tadalafil; Selexipag
    PhasePhase 3
    Registry statusCompleted